This article first appeared on GuruFocus .
-
Revenue:$497 million, up 7% year-over-year.
-
Adjusted EBITDA:$109 million, compared to $113 million in the prior year quarter.
-
Adjusted EBITDA Margin:21.9%, down from 24.4% in the prior year quarter.
-
Adjusted Earnings Per Share (EPS):$1.02, compared to $1.04 in the prior year quarter.
-
Free Cash Flow:$103 million, compared to $108 million in the prior year quarter.
-
Net Leverage:2.4x, returning to the long-term target range.
-
Life Sciences Sales:$180 million, up 11% year-over-year.
-
Personal Care Sales:$155 million, up 5% year-over-year.
-
Specialty Additives Sales:$136 million, up 4% year-over-year.
-
Intermediates Sales:$37 million, up 12% year-over-year.
-
Available Liquidity:$936 million.
Release Date: July 29, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Ashland Inc ( NYSE:ASH ) delivered a strong third quarter with a 7% year-over-year sales increase, driven by volume growth across all business units.
-
Life Sciences achieved double-digit sales growth, marking its fifth consecutive quarter of volume gains, supported by strong demand in pharma applications.
-
Personal Care reported solid performance with high single-digit growth in skincare and favorable contributions from hair care and microbial protection.
-
Specialty Additives experienced sales growth due to market share gains and strong commercial execution in coatings and performance specialties.
-
Ashland Inc ( NYSE:ASH ) generated strong cash flow during the quarter, ending with a net leverage of 2.4x, aligning with its long-term target range.
Negative Points
-
Profitability was impacted by production challenges earlier in the fiscal year, with adjusted EBITDA decreasing to $109 million from $113 million in the prior year quarter.
-
Adjusted EBITDA margin declined to 21.9% from 24.4% in the prior year quarter, reflecting lower production rates and cost pressures.
-
Intermediates segment saw a decline in adjusted EBITDA due to lower advanced manufacturing tax credits compared to the prior year.
-
Specialty Additives faced continued weakness in construction and energy markets, impacting overall performance.
-
The company revised its adjusted EPS outlook to low to mid-single-digit growth from mid to high single-digit growth due to a higher tax rate associated with unfavorable discrete items.
Q & A Highlights
Q: Can you provide insights into the pricing trends and expectations for the upcoming quarters, particularly in light of inflation and cost pressures? A: Guillermo Novo, CEO, explained that Ashland is less exposed to petrochemical-linked inflation due to the sale of its adhesive business. The company focuses on value pricing to recover inflation and maintain margins. William Whitaker, CFO, added that pricing improved from down 2% in Q2 to up 1% in Q3, with further sequential improvement expected in Q4. The pricing actions are expected to align with the 3-8% range, depending on the region and product line.
Q: How is the manufacturing optimization progressing, particularly at the Hopewell facility, and what impact will it have on fiscal 2027? A: Guillermo Novo, CEO, stated that while there have been challenges, particularly with the Hopewell facility, improvements are being made. The turnaround at Hopewell has been successful, and the focus is on ramping up production rates. The company expects to see benefits from these optimizations starting in the second quarter of fiscal 2027, with a potential 200 basis point improvement in EBITDA margins.
Q: What is the outlook for the Specialty Additives segment, given the current market conditions? A: Dago Caceres, Senior VP, noted that while market conditions remain mixed, the segment is seeing growth driven by share gains, pricing realization, and strong commercial execution. The team is focused on innovation and pipeline execution to outperform the market, with stable conditions in architectural coatings and better-than-expected performance in specialty applications.
Q: Can you elaborate on the sustainability of the pharma volume growth in the Life Sciences segment? A: Alessandra Assis, Senior VP, highlighted that the Life Sciences segment targets mid-single-digit growth, driven by globalized and innovative strategies. The company is benefiting from the growth of GLP-1 drugs and is launching a permeation enhancer to support biologics in oral formats. The underlying demand trends remain strong, supported by resilient pharmaceutical demand.
Q: What are the expectations for the Personal Care segment, and how sustainable is the current growth momentum? A: James Minicucci, Senior VP, stated that Personal Care is experiencing mid-single-digit growth, driven by volume increases and strong performance in biofunctional actives and microbial protection. The segment is benefiting from a strong pipeline and customer engagement, with expectations to maintain this momentum into fiscal 2027.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
